Metastatic Renal Cell Carcinoma Presenting as a Bleeding Gastric Polyp

Muhammad F. Mubarak, MD,1,2 Ebubekir S. Dagililar, MD,3 Thom Smilari, MD,4 Arnab Ray, MD3

1Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA 2Department of Internal Medicine, King Saud University, College of Medicine, Riyadh, Saudi Arabia 3Department of Gastroenterology and Hepatology, Ochsner Clinic Foundation, New Orleans, LA 4Department of Pathology, Ochsner Clinic Foundation, New Orleans, LA

**Background:** Renal cell carcinoma (RCC) is responsible for nearly 13,000 deaths in the United States every year, predominantly because of metastasis to other bodily organs. However, metastasis of RCC to the stomach occurs rarely; it presents as solitary or multiple polyps or as ulcers concerning for primary gastric carcinoma. Bleeding from metastasis to the stomach is a rare and underrecognized cause of gastrointestinal bleeding. We describe a case of gastrointestinal bleeding in an elderly female who was found to have a gastric polyp of RCC origin.

**Case Report:** An 83-year-old female presented to our hospital for evaluation of an acute right basal ganglia hemorrhage after falling at her nursing home. Her hospital course was notable for melenic stool and anemia. Upper endoscopy revealed a single 40-mm pedunculated polyp and active bleeding on the lesser curvature of the stomach. Polypectomy and clipping were performed. Pathology was consistent with metastatic clear cell RCC. The patient’s family declined a referral to oncology for evaluation of the newly diagnosed malignancy and opted for hospice care.

**Conclusion:** This case illustrates the potential for metastatic RCC to involve the stomach and cause gastrointestinal bleeding and anemia. The case also illustrates the role of upper gastrointestinal endoscopy in diagnosing and treating metastatic causes of gastrointestinal bleeding.

**Keywords:** Gastrointestinal hemorrhage, gastrointestinal neoplasms, intestinal polyps, neoplasm metastasis, renal cell carcinoma

**INTRODUCTION**
Renal cell carcinoma (RCC) represents 3% of all adult malignancies. The mean age at presentation is 50-70 years, with a male to female ratio of 2:1. Risk factors for developing RCC include older age; obesity; smoking; length of renal dialysis; asbestos exposure; cadmium; and some genetic syndromes, including von Hippel-Lindau syndrome, tuberous sclerosis, and familial clear cell carcinoma. Tumor cells arise from the epithelium of the proximal tubules.

RCC is responsible for more than 13,000 deaths in the United States every year, predominantly because of metastasis to other bodily organs such as the brain, liver, lung, and bone. RCC is also known to metastasize to the gastrointestinal tract. Metastasis to the stomach occurs rarely, but when it does, it presents as solitary or multiple polyps or as ulcers concerning for primary gastric carcinoma. Metastasis to the stomach is proposed to occur through lymphatic infiltration, hematogenous seeding, peritoneal dissemination, or direct contiguous invasion.

We present a case of gastrointestinal bleeding in an elderly female who was found to have a gastric polyp of RCC origin.

**CASE REPORT**
An 83-year-old female with multiple comorbidities, including stroke with residual left-sided weakness and aphasia, advanced dementia, diverticular bleeding, and diverticulitis requiring partial colectomy and colostomy, was transferred to our hospital for evaluation of an acute right basal ganglia hemorrhage after she fell at her nursing home. No neurosurgical intervention was provided given her high risk, and antiplatelet therapy was withheld. The patient’s hospital course was complicated by findings of anemia and melenic stool and blood clots in her ostomy bag. On physical examination, the patient was pale and generally ill-appearing. She had right eye ptosis, hypoxia, and tachycardia with regular rhythm but no murmurs. Her chest was clear to auscultation; her abdomen was nontender but notable for dark output in the ostomy bag. The patient’s blood count was notable for a decrease in hemoglobin and hematocrit from 9.8 g/dL and 31% at presentation to 7.0 g/dL and 20% 5 days later. Chemistry panel was unremarkable, and the patient had a normal coagulation profile.
Upper endoscopy revealed a single 40-mm pedunculated polyp with active bleeding and stigmata of recent bleeding on the lesser curvature of the stomach (Figure 1). Polypectomy using the epinephrine injection-lift technique was followed by hot snare resection with complete removal (Figure 2). Two hemostatic clips were placed to prevent postpolypectomy bleeding (Figure 3).

Immunohistochemical staining with vimentin was positive for epithelial membrane antigen and CD10 (Figure 4). RCC antigen stain was focally positive. Pan-cytokeratin was negative, and CD68 staining showed scattered histiocytes. Histopathology and immunohistochemical staining were consistent with metastatic clear cell RCC.

The biopsy results were discussed with the patient’s son and primary care physician. The patient’s family was offered referral to oncology for evaluation and possible palliation of the newly diagnosed cancer, but they refused because of the patient’s multiple medical comorbidities and opted for hospice care.

DISCUSSION

Metastasis of RCC to the stomach is a rare clinical finding. A case published in 2012 noted that only 19 cases had been reported in the literature. One review reported that patients with gastric metastasis had an average age at presentation of 59.1 years (range 56–71 years) with metastasis occurring 16-78 months since the diagnosis of a primary malignancy. Metastasis from RCC usually lags 50-78 months from initial diagnosis of RCC. Metastatic RCC has been reported to present in the form of upper gastrointestinal bleeding (65%) and iron-deficiency anemia (35%).

Symptoms of gastric metastasis include dysphagia, epigastric pain, and vomiting. Although presentation can vary widely, a significant number of patients are diagnosed after presenting with gastrointestinal bleeding similar to our patient. Endoscopic findings of gastric metastasis are predominantly submucosal and solitary. Nevertheless, lesions can be polypoidal (similar to our case) or ulcerated protruding lesions. Adequate biopsy sampling is of paramount importance given the lack of description of mucosal and submucosal pits in the endoscopic classification system.

Treatment options for metastatic RCC include surgery and chemotherapy. Prognosis following a diagnosis of gastric metastasis is usually poor, with a median survival of 3 months and a range of 1-11 months, although solitary metastasis was correlated with a longer median survival in one case series study.
Metastatic RCC is considered a metabolic disease through abnormal alteration of oxygen-sensing metabolic pathways that leads to upregulating hypoxia-inducible factor (HIF) pathways and HIF-related genes including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and epidermal growth factor.\textsuperscript{10} Evidence has shown that HIF1\textalpha{} has a role in tumor suppression, while HIF2\textalpha{} has an oncogenic role.\textsuperscript{11} Gene expression and single nucleotide polymorphism (SNP) in patients with metastatic RCC have been studied to determine overall survival through treatment with the standard chemotherapy agent sunitinib.\textsuperscript{12-15} SNPs in VEGF and VEGF receptors have shown no statistically significant outcome other than VEGF receptor-1 SNP rs9582936 with increased overall survival.\textsuperscript{12,16} The expression of PDGF receptor beta in metastatic RCC allows for therapeutic targeting with sorafenib, another chemotherapeutic agent used to treat patients with metastatic RCC, and thus improves overall survival.\textsuperscript{17} Sunitinib malate is a tyrosine kinase inhibitor of angiogenic receptors commonly upregulated in metastatic RCC, including PDGF receptors, c-KIT, FMS-like tyrosine kinase receptor 3 (FLT3), VEGF receptor-1, and VEGF receptor-2. Sunitinib is currently the first-line treatment for patients with metastatic RCC, and since its introduction, has significantly improved overall survival and clinical outcomes.\textsuperscript{3,4,12-15,18}

CONCLUSION
This case highlights the potential for metastatic RCC involvement of the stomach, with resulting gastrointestinal bleeding and anemia. Gastric metastatic RCC usually lags primary tumor growth by years and generally entails a poor prognosis. This case also illustrates the role of upper gastrointestinal endoscopy in diagnosing and treating metastatic causes of upper gastrointestinal bleeding.

ACKNOWLEDGMENTS
The authors have no financial or proprietary interest in the subject matter of this article.

REFERENCES
1. Xu J, Latif S, Wei S. Metastatic renal cell carcinoma presenting as gastric polyps: a case report and review of the literature. Int J Surg Case Rep. 2012;3(12):601-604. doi: 10.1016/j.ijscr.2012.08.009.
2. Sadler GJ, Anderson MR, Moss MS, Wilson PG. Metastases from renal cell carcinoma presenting as gastrointestinal bleeding: two case reports and a review of the literature. BMC Gastroenterol. 2007 Jan 31;7:4. doi: 10.1186/1471-230X-7-4.
3. Weigt J, Malfertheiner P. Metastatic disease in the stomach. Gastrointest Tumors. 2015 Sep;2(2):61-64. doi: 10.1159/000431304.
4. Dufies M, Giuliani S, Ambrosetti D, et al. Sunitinib stimulates expression of VEGFC by tumor cells and promotes lymphangiogenesis in clear cell renal cell carcinomas. Cancer Res. 2017 Mar 1;77(5):1212-1226. doi: 10.1158/0008-5472.CAN-16-3088.
5. Namikawa T, Hanazaki K. Clinicopathological features and treatment outcomes of metastatic tumors in the stomach. Surg Today. 2014 Aug;44(8):1392-1399. doi: 10.1007/s00595-013-0671-9.
6. Kim GH, Ahn JY, Jung HY, et al. Clinical and endoscopic features of metastatic tumors in the stomach. Gut Liver. 2015 Sep 23;9(5):615-622. doi: 10.5009/gnl14032.
7. Shaaban H, Modi Y, Modi T, Gurun G. Diffuse gastroduodenal metastasis from cutaneous malignant melanoma presenting as amelanotic “volcano-like” ulcers. J Gastrointest Cancer. 2014 Mar;45(1):116-117. doi: 10.1007/s12029-013-9515-5.
8. Oda I, Kondo H, Yamao T, et al. Metastatic tumors to the stomach: analysis of 54 patients diagnosed at endoscopy and 347 autopsy cases. Endoscopy. 2001 Jun;33(6):507-510.
9. Onorati M, Petracco G, Uboldi P, et al. A solitary polypoid gastric metastasis 20 years after renal cell carcinoma: an event to be considered, and a brief review of the literature. Pathologica. 2013 Aug;105(4):132-136.
10. Ciccarese C, Brunelli M, Montironi R, et al. The prospect of precision therapy for renal cell carcinoma. Cancer Treat Rev. 2016 Sep;49:37-44. doi: 10.1016/j.ctrv.2016.07.003.
11. Go H, Kang MJ, Kim PJ, et al. Development of response classifier for vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitor (TKI) in metastatic renal cell carcinoma. Pathol Oncol Res. 2017 Sep 29. doi: 10.1007/s12253-017-0323-2. [Epub ahead of print].
12. Dombusch J, Walter M, Gottschalk A, et al. Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients. J Cancer Res Clin Oncol. 2016 Jun;142(6):1171-1182. doi: 10.1007/s00432-016-2137-0.
13. Kontovinis LF, Papazisis KT, Touplikioti P, Andreasis C, Mouratidou D, Kortsaris AH. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer. 2009 Mar 12;9:82. doi: 10.1186/1471-2407-9-82.
14. Négrier S, Raymond E. Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs. 2012 Aug;30(4):1791-1801. doi: 10.1007/s10637-011-9677-6.
15. Zucca LE, Morini Matushita MA, da Silva Oliveira RJ, et al. Expression of tyrosine kinase receptor AXL is associated with worse outcome of metastatic renal cell carcinomas treated with sunitinib. Urol Oncol. 2018 Jan;36(1):11.e13-11.e21. doi: 10.1016/j.urolonc.2017.09.003.
16. Miao C, Cao J, Wang Y, Liu B, Wang Z. Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis. Oncotarget. 2017 Aug 4;8(40):68854-68862. doi: 10.18632/oncotarget.19924.
17. Merseburger AS, Simon A, Waalkes S, Kuczyk MA. Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther. 2009 Oct;9(10):1429-1434. doi: 10.1586/era.09.96.
18. Kapoor A. First-line treatment options in metastatic renal cell cancer. Can Urol Assoc J. 2016 Nov-Dec;10(11-12Suppl7):S236-S238. doi: 10.5489/cuaj.4307.

This article meets the Accreditation Council for Graduate Medical Education and the American Board of Medical Specialties Maintenance of Certification competencies for Patient Care and Medical Knowledge.